News

10 Nov 2020
Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT^® Technology – is Published by Public Health England and Oxford Immunotec

READ MORE

5 Nov 2020
Oxford Immunotec Files Submission to Food and Drug Administration (FDA) for the T-Cell Select^™ Reagent Kit



READ MORE

22 Oct 2020
UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials

READ MORE

29 Sep 2020
Oxford Immunotec Announces Food and Drug Administration (FDA) Clearance of the T-SPOT^®.TB Test for Use in Pediatrics Over the Age of Two

READ MORE

20 Sep 2020
Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT^® Discovery^TM SARS-CoV-2 Test


READ MORE

20 Jul 2020
Oxford Immunotec Announces Agreement with Stop TB Partnership – Global Drug Facility (GDF) to Provide Access to the T-SPOT^®.TB Test for 100+ TB Burden Countries

READ MORE